Myriad Genetics welcomes you to the 2024 ASCO® Annual Meeting

Your partner for genetic and genomic testing

As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease. Myriad understands the complexities and challenges you face in treating patients with cancer. That’s why we’ve developed innovative germline and somatic testing technologies that inform and identify treatment options for your patients—quickly and accurately.

Consolidated germline and somatic results, delivered fast

Reduced variant discordance by cross-checking between germline and somatic results

Simplified workflow solutions customizable to your practice

Meet our leadership team

Visit us at Booth 25014 to learn more about how Myriad can advance your treatment solutions. Our leadership team will be on site during the below times to meet with you and answer any questions you may have.

Saturday, June 1st

9:30 am

George W. Daneker, Jr. MD

President and chief clinical officer of oncology

12:30 pm

Kirsten Timms, PhD

Senior Vice President of Biomarker Discovery

Sunday, June 2nd

9:30 am

Paul Diaz

Chief Executive Officer and President of Myriad Genetics

12:30 pm

Dale Muzzey, PhD

Chief Scientific Officer

Unable to connect with us during these times? Complete the form below to let us know you still want to speak with a Myriad expert.

Learn from our experts

We are committed to providing you with a valuable and enriching experience while at the annual meeting. This year, learn from experts and discover how our comprehensive testing solutions revolutionize cancer care.

Oral abstract session

Prevention, risk reduction, and genetics

Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women Presenter: Holly J. Pederson, MD | Cleveland Clinic

Poster sessions

Connect with us

Get started with Myriad Oncology

Request more information about how Myriad’s Oncology solutions can benefit you/your patients.

Don't know your NPI? Click Here
Don't know your NPI? Click Here

You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.

Hidden Fields

Hidden test fields

Myriad Collaborative Research Registry

Learn how Myriad is working to advance patient care through the Myriad Collaborative Research Registry—one of the largest pan-cancer registries freely available for research use.

Precise Molecular Residual Disease (MRD) Test

Myriad’s Precise MRD test is whole genome sequencing (WGS)-based, enabling the custom selection of hundreds to thousands of targeted variants for deep analysis. It has impressive limits of detection and excellent sensitivity, ensuring exceptional performance. This test is currently available for research use only (RUO).

The Myriad Oncology portfolio offers testing solutions for every step in your patients’ and their families’ journeys

  • Germline Tests

    Germline hereditary cancer test capable of identifying risk and providing insights for treatment options for 11 hereditary cancers.

  • Tumor Profiling

    Precise Tumor is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors.

  • Genomic prognostic test for patients newly diagnosed with early-stage, estrogen-receptor-positive, HER2-negative breast cancer.

  • Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.

  • HRD Status

    The most comprehensive FDA-approved tumor test that determines HRD status in women with ovarian cancer.

  • FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic and prostate cancer.

  • IHC Stains

    FDA-approved assay to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab*

  • Offered together with Precise Tumor to measure protein expression and identify patients who may benefit from immunotherapy

Previous Test
    Next Test